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Ankle Brachial Index Combined
With Framingham Risk Score to Predict
Cardiovascular Events and Mortality
A Meta-analysis
Ankle Brachial Index Collaboration
MAJOR CARDIOVASCULARand cerebrovascularevents includingmyocar-dial infarction and stroke
often occur in individuals without
known preexisting cardiovascular dis-
ease. The prevention of such events, in-
cluding the accurate identification of
those at risk,1 remains a serious public
health challenge. Scoring equations to
predict those at increased risk have been
developed using cardiovascular risk
factors, including cigarette smoking,
blood pressure, total and high-density
lipoprotein cholesterol, and diabetes
mellitus. The Framingham risk score
(FRS)2,3 is often considered the refer-
ence standard but has limited accu-
racy, tending tooverestimate risk in low-
risk populations andunderestimate risk
in high-risk populations.4 The incorpo-
ration of other riskmarkers, such as the
metabolic syndrome5 and plasma C-
reactive protein,6,7 has had partial suc-
cess in improving prediction, and atten-
tion also is being given to indicators of
asymptomatic atherosclerosis, such as
coronary artery calcium, carotid in-
timamedia thickness, and the ankle bra-
chial index (ABI).1
The ABI, which is the ratio of sys-
tolic pressure at the ankle to that in the
arm, is quick and easy to measure and
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Context Prediction models to identify healthy individuals at high risk of cardiovas-
cular disease have limited accuracy. A low ankle brachial index (ABI) is an indicator of
atherosclerosis and has the potential to improve prediction.
Objective To determine if the ABI provides information on the risk of cardiovascu-
lar events and mortality independently of the Framingham risk score (FRS) and can
improve risk prediction.
Data Sources Relevant studies were identified. A search of MEDLINE (1950 to Feb-
ruary 2008) and EMBASE (1980 to February 2008) was conducted using common text
words for the term ankle brachial index combined with text words and Medical Sub-
ject Headings to capture prospective cohort designs. Review of reference lists and con-
ference proceedings, and correspondence with experts was conducted to identify ad-
ditional published and unpublished studies.
Study Selection Studies were included if participants were derived from a general
population, ABI was measured at baseline, and individuals were followed up to detect
total and cardiovascular mortality.
Data Extraction Prespecified data on individuals in each selected study were ex-
tracted into a combined data set and an individual participant data meta-analysis was
conducted on individuals who had no previous history of coronary heart disease.
Results Sixteen population cohort studies fulfilling the inclusion criteria were
included. During 480 325 person-years of follow-up of 24 955 men and 23 339
women, the risk of death by ABI had a reverse J-shaped distribution with a normal
(low risk) ABI of 1.11 to 1.40. The 10-year cardiovascular mortality in men with a low
ABI (0.90) was 18.7% (95% confidence interval [CI], 13.3%-24.1%) and with nor-
mal ABI (1.11-1.40) was 4.4% (95% CI, 3.2%-5.7%) (hazard ratio [HR], 4.2; 95%
CI, 3.3-5.4). Corresponding mortalities in women were 12.6% (95% CI, 6.2%-
19.0%) and 4.1% (95% CI, 2.2%-6.1%) (HR, 3.5; 95% CI, 2.4-5.1). The HRs
remained elevated after adjusting for FRS (2.9 [95% CI, 2.3-3.7] for men vs 3.0
[95% CI, 2.0-4.4] for women). A low ABI (0.90) was associated with approximately
twice the 10-year total mortality, cardiovascular mortality, and major coronary event
rate compared with the overall rate in each FRS category. Inclusion of the ABI in car-
diovascular risk stratification using the FRS would result in reclassification of the risk
category and modification of treatment recommendations in approximately 19% of
men and 36% of women.
Conclusion Measurement of the ABI may improve the accuracy of cardiovascular
risk prediction beyond the FRS.
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has been used for many years in vascu-
lar practice to confirm the diagnosis and
assess the severity of peripheral artery
disease in the legs. Most commonly the
ABI is calculated by measuring the sys-
tolic bloodpressure in theposterior tibial
and/or the dorsalis pedis arteries either
in both legs or 1 leg chosen at random
(using a Doppler probe or alternative
pulse sensor), with the lowest ankle
pressure then divided by the brachial
systolic blood pressure. In addition to
peripheral artery disease, the ABI also is
an indicator of generalized atheroscle-
rosis because lower levels have been as-
sociated with higher rates of concomi-
tant coronary and cerebrovascular
disease, and with the presence of car-
diovascular risk factors.8 In population
cohort studies in theUnitedStates9-12 and
Europe,13-17 a low ABI has been related
to an increased incidence of mortality
(total and cardiovascular), myocardial
infarction, and stroke. These increased
relative risks have been shown to be in-
dependentofbaseline cardiovasculardis-
ease and risk factors, suggesting that the
ABI might have an independent role in
predicting cardiovascular events.
The objective of our studywas to de-
termine if the ABI provides informa-
tion on the risk of cardiovascular events
andmortality independently of the FRS
and can improve risk prediction. To en-
hance the representativeness of our
study and tomaximize participant num-
bers, we formed the Ankle Brachial In-
dexCollaborationwith the intent of in-
cluding all major observational studies
that had investigated longitudinally the
ABI and incidence of cardiovascular
events and mortality in general popu-
lations. At the same time we wished to
identify a normal (low risk) level of the
ABI that could be used in future stud-
ies and in clinical practice.
METHODS
The study designwas an individual par-
ticipantdatameta-analysisofpopulation-
based cohort studies. The criteria for
study inclusionwere that the study con-
tainedparticipants of any age and sexde-
rived from a general population (ie, not
a specific disease group), ABI was mea-
sured at baseline using a technique stan-
dardized in each study, and individuals
were followed up systematically to de-
tect total and cardiovascular mortality.
At initial meetings of epidemiolo-
gists interested in the ABI, studies ful-
filling the inclusion criteria were iden-
tified. A search was conducted of
MEDLINE from1950 to February 2008
and EMBASE from 1980 to February
2008. Reference lists and conference
proceedings alsowere searched to iden-
tify possible additional studies. The fol-
lowing search termswereused:ABPI.tw,
ABI.tw, AAI.tw, ankle brachial pressure
index $.tw, ankle brachial pressure$.tw,
ankle brachial index$.tw. (or ankle bra-
chial index/), ankle arm index$.tw, ankle
arm blood pressure$.tw, ankle arm blood
pressure index$.tw, ankle blood pres-
sure$.tw, follow up stud$.tw, follow up
studies/ or follow up/, epidemiological
stud$.tw, epidemiological studies/ or epi-
demiology/, cohort$.tw, cohort analy-
sis/ or cohort studies/.
Further studies andunpublisheddata
were sought by discussion between col-
laborators, cardiovascular epidemiolo-
gists, and vascular physicians and by
correspondence with the Asia Pacific
Cohort Studies Collaboration. Pos-
sible studies for inclusion were inde-
pendently assessed for suitability by 2
collaborators (G.F. and J.P.) and any
lack of clarity or disagreement was re-
solved by discussion.
The principal authors or lead inves-
tigators of studies were invited to join
the ABI Collaboration and, following
acceptance, were sent a questionnaire
enquiring about the availability of
specific study data. On reviewing re-
sponses to these questionnaires, a set
of data that were commonly available
was agreed on, and each study trans-
ferred their relevant data to the coor-
dinating center.
Requested data included individual
demographic characteristics (eg, sex,
age, height, andweight), baseline clini-
cal cofactors (eg, systolic and diastolic
bloodpressure, cholesterol, diabetes, and
cigarette smoking), details of baseline
ABImeasurements, and information on
nonfatal and fatal events during follow-
up. For these analyses, the participants
included had no previous history of
coronary heart disease (CHD) as de-
fined in each study, a value for ABI re-
corded at baseline, and follow-up dates
or times to events. Data from collabo-
ratorswere extracted andanalyzedusing
SPSS version 14 (SPSS Inc, Chicago, Il-
linois) and SAS version 9.1 (SAS Insti-
tute Inc, Cary, North Carolina).
A FRS was derived for each indi-
vidual using the sex-specific predic-
tion formulas proposed byWilson et al3
based on conventional cardiovascular
risk factors (age, total and high-
density lipoprotein cholesterol catego-
ries, blood pressure categories, diabe-
tes, and smoking status).When data on
some of the variables necessary to cal-
culate the FRS were incomplete, miss-
ing values, amounting to 3.9% of total
values, were imputed using the expec-
tation-maximizationprocedure formul-
tivariate normal data, which is imple-
mented in SPSS.
Overall (all studies combined) haz-
ard ratios (HRs) forABI, subdivided into
10 categories compared with a refer-
ence rangeof1.11 to1.20,wereobtained
for men and women for each of 3 out-
comes of totalmortality, cardiovascular
mortality, andmajorcoronaryevents (ie,
coronary death, nonfatal myocardial
infarction), and patterns of risk exam-
ined. Coronary revascularization and
anginawere not included as end points.
The HRs for low vs normal ABI, which
was categorized into 4 groups for the 3
outcomes of total mortality, cardiovas-
cular mortality, and major coronary
events were obtained from a propor-
tionalhazardsmodel stratifiedbysexand
study, bothunadjusted and adjusted for
FRS (categorized into 5 strata for men
and4 forwomen).TheseHRswere then
pooledusingarandom-effectsmodeland
summarized using forest plots (Review
Manager version 4.2.9, Cochrane Col-
laboration, Oxford, England).
Kaplan-Meier estimates and stan-
dard errors for outcome rates (total
mortality, cardiovascularmortality, and
major coronary events) at 10 yearswere
obtained for each study stratified by sex
and categories for FRS and ABI. Out-
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come rates for studieswithin stratawere
combined to provide overall summa-
ries using random-effects pooling.18
Area under receiver operating charac-
teristic curves were calculated for the
prediction of events using the FRS alone
and with the addition of the ABI.
RESULTS
The literature search and information
from experts identified 1075 citations
fromwhich 20 studies that fulfilled the
inclusion criteria were identified
(FIGURE 1). Selected investigators from
16 of these studies9-17,19-25 agreed to par-
ticipate in the ABI Collaboration and
provided data prior to the analysis. The
participating studies and investigators
are listed at the end of this article. The
studies were based in Australia, Bel-
gium, Italy, Netherlands, Sweden, the
United Kingdom, and theUnited States
and comprised predominantly white
populations except for the Honolulu
Heart Program ( Japanese Ameri-
cans)11 and the Strong Heart Study
(American Indians).12 The popula-
tions in the Cardiovascular Health
Study10 and the Atherosclerosis Risk in
Communities Study9 comprised 15%
and 26%blacks, respectively. In the San
Luis Valley Diabetes Study,24 the in-
cluded healthy populationwithout dia-
betes was 42% Hispanic. Eleven stud-
ies included both sexes, 4 included only
men, and 1 included only women.
The characteristics of the partici-
pants in the studies at baselinewhen the
ABIwasmeasured are shown inTABLE1.
A total of 24955menand23339women
without a history of CHD were in-
cluded. They were late middle aged to
elderly with a mean age in the studies
ranging from 47 to 78 years. The 10-
year mean (SD) incidence of CHD pre-
dicted by the FRS at baseline varied
across studies from 11.0% (6.1%) to
31.6% (14.1%) in men and from 7.1%
(6.1%) to14.5%(10.1%) inwomen.The
mean (SD) ABI was greater than 1.00 in
all studies and ranged from 1.02 (0.13)
to 1.21 (0.13) inmen and 1.01 (0.16) to
1.15 (0.17) inwomen;most of the stud-
ies comprising both sexes had higher
mean values in men than in women, as
previously reported.24
TABLE 2 and TABLE 3 show the total
mortality, cardiovascularmortality, and
major coronary events occurring dur-
ing follow-up in each of the studies for
men and women, respectively. Median
duration of follow-up ranged from 3 to
Figure 1. Flow Diagram of Selection of
Studies for Inclusion in Meta-analysis
20 Studies eligible for inclusion
in meta-analysis
55 Full-text articles considered
for inclusion
1075 Citations identified in MEDLINE
and EMBASE and through
expert suggestion
16 Studies with complete and validated
data included in meta-analysis
4 Excluded (did not have data
available for inclusion in
meta-analysis)
35 Excluded due to not fulfilling
inclusion criteria and
duplicate articles of studies
1020 Excluded due to title and
abstract not fulfilling
inclusion criteria
Table 1. Baseline Characteristics of Individuals in Studies in the Ankle Brachial Index (ABI) Collaboration
Source Study
No. of Individualsa
Mean (SD)
Age, y
FRS, %b ABI
Men
(n = 24955)
Women
(n = 23339) Men Women Men Women
Weatherley et al,9 2007 ARIC 6105 8004 54 (5.7) 12.8 (7.6) 7.3 (6.0) 1.17 (0.13) 1.12 (0.13)
Kornitzer et al,17 1995 Belgian Physical Fitness 2068 0 47 (4.4) 11.0 (6.1) NA 1.21 (0.13) NA
Newman et al,10 1999 Cardiovascular Health 1846 2779 73 (5.5) 25.4 (12.5) 8.0 (5.3) 1.10 (0.19) 1.06 (0.15)
Leng et al,13 1996 Edinburgh Artery 690 702 64 (5.7) 26.2 (13.0) 11.5 (6.2) 1.07 (0.19) 1.01 (0.16)
Murabito et al,19 2002 Framingham Offspring 1423 1703 58 (9.6) 15.3 (10.3) 7.5 (5.9) 1.16 (0.12) 1.10 (0.10)
Fowler et al,20 2002 Health in Men 2771 0 72 (4.4) 29.4 (9.6) NA 1.07 (0.17) NA
Abbott et al,11 2000 Honolulu Heart Program 3123 0 78 (4.6) 31.6 (14.1) NA 1.05 (0.17) NA
Jager et al,21 1999 Hoorn 270 284 63 (7.2) 26.8 (13.9) 14.5 (10.1) 1.03 (0.14) 1.02 (0.12)
McDermott et al,22 2004 InCHIANTI 481 569 67 (15.5) 24.8 (15.4) 8.0 (5.8) 1.04 (0.16) 1.05 (0.14)
Hooi et al,14 2004 Limburg PAOD 1031 1320 57 (9.4) 20.2 (10.6) 11.7 (5.8) 1.08 (0.16) 1.07 (0.13)
Ogren et al,15 1993 Men Born in 1914 391 0 69 (0.5) 31.5 (10.5) NA 1.02 (0.13) NA
Van der Meer et al,16 2004 Rotterdam 2134 3515 69 (9.2) 29.6 (15.6) 10.2 (7.2) 1.10 (0.21) 1.05 (0.21)
Criqui et al,23 1992 San Diego 244 314 66 (10.4) 21.6 (12.9) 7.8 (5.1) 1.08 (0.19) 1.02 (0.12)
Hiatt et al,24 1995 San Luis Valley Diabetes 674 838 53 (12.1) 15.6 (12.0) 9.1 (9.4) 1.16 (0.15) 1.10 (0.14)
Resnick et al,12 2004 Strong Heart 1704 2622 56 (8.0) 15.5 (9.6) 10.8 (7.3) 1.15 (0.14) 1.15 (0.17)
McDermott et al,25 2000 Women’s Health and Aging 0 689 78 (8.1) NA 7.1 (6.1) NA 1.05 (0.21)
Abbreviations: ARIC, Atherosclerosis Risk in Communities; FRS, Framingham risk score; InCHIANTI, Invecchiare in Chianti; NA, not applicable; PAOD, peripheral arterial occlusive
disease.
aNo history of coronary heart disease (including myocardial infarction, angina, and revascularization as defined in each study), ABI available at baseline, and follow-up data available.
bPredicted percentage at 10 years for incidence of coronary heart disease, including coronary death, myocardial infarction, and angina.
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16.7 years, with 9 of the 16 studies hav-
ing more than 10 years of follow-up.
Overall, 9924 deaths occurred during
480 325 person-years of follow-upwith
aroundone-quarterofdeathsduetoCHD
or stroke in both men and women. The
annual rates of deaths and events varied
considerably between the studies. For
example,menin theBelgianPhysicalFit-
ness Study had a mean (SD) age of 47
(4.4) years and the annualmortalitywas
0.37% (95% confidence interval [CI],
0.29%-0.45%), whereas men in the
Honolulu Heart Program had a mean
(SD)ageof78 (4.6)years and theannual
mortality was 4.91% (95% CI, 4.59%-
5.22%) (Table 2). Likewise, for women
annual mortality varied between 0.55%
(95%CI, 0.42%-0.68%) in theFraming-
hamOffspringStudyand7.34%(95%CI,
6.39%-8.29%) in the Women’s Health
and Aging Study (Table 3).
The HRs for death for different levels
ofABI comparedwith a referenceABI of
1.11 to 1.20 in all studies combined
formeda reverse J-shapedcurve forboth
men andwomen (FIGURE 2). For levels
of ABI below 1.11, the HRs increased
consistently with decreasing ABI. For
anABIof greater than1.40, theHRs also
were increased in men (1.38; 95% CI,
1.17-1.62) and in women (1.23; 95%
CI, 1.00-1.52). For levels of ABI from
1.11 to1.40, only small andmostlynon-
significant differences in HRs were
found. TABLE 4 and TABLE 5 show the
HRs for total and cardiovascular mor-
tality andmajor coronary events byABI
in men and women, respectively. The
patterns of risk for cardiovascularmor-
tality and major coronary events were
similar to that for totalmortality; for lev-
els of ABI below 1.11, the HRs for car-
diovascular mortality were consis-
tently higher than for total mortality.
Values of the ABI less than 0.90 have
been taken traditionally as a measure
of increased risk. In nearly all the stud-
ies inmen (FIGURE 3), the HRs for total
mortality were statistically signifi-
cantly higher in individualswith anABI
of 0.90 or less comparedwith individu-
als with normal ABI values of 1.11 to
1.40 (HR, 3.33; 95%CI, 2.74-4.06). In
women, the results were more hetero-
geneous (FIGURE 4), but theHR of 2.71
(95% CI, 2.03-3.62) was comparable
Table 2. Total Mortality, Cardiovascular Mortality, and Major Coronary Events for Men in Studies in the Ankle Brachial Index Collaboration
Study
Follow-up,
Median
(IQR), y
Total Mortality Cardiovascular Mortalitya Major Coronary Eventsb
Person-
Years of
Follow-up
(n = 233457)
No. of
Deaths
(n = 5582)
Annual
Mortality,
%
(95% CI)
Person-
Years of
Follow-up
(n = 233457)
No. of
Deaths
(n = 1507)
Annual
Mortality,
%
(95% CI)
Person-
Years of
Follow-up
(n = 205628)
No. of
Events
(n = 2255)
Annual
Events,
%
(95% CI)
ARIC9 13.1
(12.4-13.9)
76497 903 1.18
(1.10-1.26)
76497 170 0.22
(0.19-0.26)
73991 571 0.77
(0.71-0.83)
Belgian
Physical
Fitness17
10.9
(10.5-11.4)
22292 83 0.37
(0.29-0.45)
22292 13 0.06
(0.03-0.09)
22136 98 0.44
(0.36-0.53)
Cardiovascular
Health10
11.0
(7.2-11.6)
16583 839 5.06
(4.73-5.39)
16583 263 1.59
(1.40-1.78)
15542 432 2.78
(2.52-3.04)
Edinburgh
Artery13
15.5
(9.0-15.9)
8667 295 3.40
(3.02-3.79)
8667 84 0.97
(0.76-1.18)
8090 113 1.40
(1.14-1.65)
Framingham
Offspring19
7.4
(6.6-8.2)
10182 113 1.11
(0.91-1.31)
10182 20 0.20
(0.11-0.28)
10052 56 0.56
(0.41-0.70)
Health in
Men20
6.3
(5.9-6.5)
16446 402 2.44
(2.21-2.68)
16446 114 0.69
(0.57-0.82)
NA NA NA
Honolulu Heart
Program11
6.2
(5.5-6.9)
17976 882 4.91
(4.59-5.22)
17976 231 1.29
(1.12-1.45)
17703 205 1.16
(1.00-1.32)
Hoorn21 12.5
(9.8-13.1)
2969 88 2.96
(2.35-3.57)
2969 26 0.88
(0.54-1.21)
NA NA NA
InCHIANTI22 3.0
(2.9-3.1)
1427 30 2.10
(1.36-2.85)
1427 11 0.77
(0.32-1.22)
NA NA NA
Limburg
PAOD14
7.1
(6.6-7.7)
7088 148 2.09
(1.76-2.42)
7088 34 0.48
(0.32-0.64)
6864 82 1.19
(0.94-1.45)
Men Born in
191415
13.3
(8.1-13.9)
4248 182 4.28
(3.68-4.89)
4248 70 1.65
(1.26-2.03)
4028 92 2.28
(1.82-2.75)
Rotterdam16 10.9
(8.2-11.8)
20538 813 3.96
(3.70-4.23)
20538 221 1.08
(0.94-1.23)
19805 260 1.31
(1.15-1.47)
San Diego23 16.7
(10.4-22.3)
3843 156 4.06
(3.44-4.68)
3843 77 2.00
(1.56-2.45)
3581 80 2.23
(1.75-2.72)
San Luis Valley
Diabetes24
15.6
(14.4-16.9)
9765 167 1.71
(1.45-1.97)
9765 51 0.52
(0.38-0.67)
9265 82 0.89
(0.69-1.08)
Strong Heart12 9.7
(8.9-10.4)
14935 481 3.22
(2.94-3.50)
14935 122 0.82
(0.67-0.96)
14573 184 1.27
(1.09-1.46)
Abbreviations: ARIC, Atherosclerosis Risk in Communities; CI, confidence interval; InCHIANTI, Invecchiare in Chianti; IQR, interquartile range; NA, data not available; PAOD, peripheral
arterial occlusive disease.
aDefined as death due to coronary heart disease or stroke.
bDefined as myocardial infarction or deaths from coronary heart disease.
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with that in men. Likewise, signifi-
cantly increasedHRswere found inmen
and in women both for cardiovascular
mortality (men: 4.21 [95% CI, 3.29-
5.39]; women: 3.46 [95% CI, 2.36-
5.08]), and for major coronary events
(men: 2.97 [95%CI, 2.33-3.78]; wom-
en: 3.05 [95% CI, 2.25-4.15]). Adjust-
ment of theHRs for individuals with an
ABI of 0.90 or less relative to an ABI of
1.11 to 1.40 for FRS reduced the HRs
but they were still elevated substan-
tially and significantly. The adjusted
HRs for total mortality were 2.34 (95%
CI, 1.97-2.78) inmen vs 2.35 (95%CI,
1.76-3.13) in women; cardiovascular
mortality, 2.92 (95% CI, 2.31-3.70) in
men vs 2.97 (95% CI, 2.02-4.35) in
women; and major coronary events,
2.16 (95%CI, 1.76-2.66) inmen vs 2.49
(95% CI, 1.84-3.36) in women.
TABLE 6 andTABLE 7 show the effect
of inclusion of an ABImeasurement on
the apparent risk of 10-year total mor-
tality, cardiovascularmortality, andma-
jor coronary events over the range of
FRS categories in men and women, re-
spectively. Compared with the overall
rates without ABI included, an ABI of
0.90 or lesswas associatedwith a greatly
increased risk of mortality (total and
cardiovascular) and major coronary
events across all FRS categories in both
men and women, but more so in the
Figure 2. Hazard Ratios for Total Mortality in Men and Women by Ankle Brachial Index at
Baseline for All Studies Combined in the ABI Collaboration
8.0
1.0
2.0
4.0
0.5
Ankle Brachial Index
H
az
ar
d 
R
at
io
 (9
5%
 C
on
fid
en
ce
 In
te
rv
al
) Men
Women
≤ 0.60 > 1.400.61-0.70 0.71-0.80 0.81-0.90 0.91-1.00 1.01-1.10 1.11-1.20 1.21-1.30 1.31-1.40
(Reference)
Hazard ratios are not adjusted for age or cardiovascular risk factors.
Table 3. Total Mortality, Cardiovascular Mortality, and Major Coronary Events for Women in Studies in the Ankle Brachial Index Collaboration
Study
Follow-up,
Median
(IQR), y
Total Mortality Cardiovascular Mortalitya Major Coronary Eventsb
Person-
Years of
Follow-up
(n = 246868)
No. of
Deaths
(n = 4342)
Annual
Mortality,
%
(95% CI)
Person-
Years of
Follow-up
(n = 246868)
No. of
Deaths
(n = 1211)
Annual
Mortality,
%
(95% CI)
Person-
Years of
Follow-up
(n = 238066)
No. of
Events
(n = 1629)
Annual
Events,
%
(95% CI)
ARIC9 13.2
(12.4-13.9)
102458 773 0.75
(0.70-0.81)
102458 133 0.13
(0.11-0.15)
101121 362 0.36
(0.32-0.39)
Cardiovascular
Health10
11.2
(8.3-11.6)
27447 851 3.10
(2.90-3.31)
27447 262 0.95
(0.84-1.07)
26652 374 1.40
(1.26-1.54)
Edinburgh
Artery13
15.8
(14.2-16.1)
9836 200 2.03
(1.75-2.31)
9836 41 0.42
(0.29-0.54)
9602 57 0.59
(0.44-0.75)
Framingham
Offspring19
7.4
(6.6-8.3)
12344 68 0.55
(0.42-0.68)
12344 5 0.04
(0.01-0.08)
12272 24 0.20
(0.12-0.27)
Hoorn21 12.6
(10.6-13.2)
3212 76 2.37
(1.84-2.89)
3212 23 0.72
(0.42-1.01)
NA NA NA
InCHIANTI22 3.0
(2.9-3.2)
1711 26 1.52
(0.94-2.10)
1711 12 0.70
(0.31-1.10)
NA NA NA
Limburg
PAOD14
7.1
(6.7-7.6)
9273 114 1.23
(1.01-1.45)
9273 26 0.28
(0.17-0.39)
9168 53 0.58
(0.42-0.73)
Rotterdam16 11.1
(9.3-12.1)
35407 1131 3.19
(3.01-3.38)
35407 352 0.99
(0.89-1.10)
34968 283 0.81
(0.72-0.90)
San Diego23 19.6
(13.0-22.6)
5443 177 3.25
(2.78-3.72)
5443 76 1.40
(1.08-1.71)
5361 65 1.21
(0.92-1.51)
San Luis Valley
Diabetes24
15.8
(14.6-17.1)
12542 163 1.30
(1.10-1.50)
12542 53 0.42
(0.31-0.54)
12293 58 0.47
(0.35-0.59)
Strong Heart12 9.9
(9.1-10.7)
24305 551 2.27
(2.08-2.45)
24305 137 0.56
(0.47-0.66)
24010 183 0.76
(0.65-0.87)
Women’s
Health and
Aging25
5.0
(3.8-5.1)
2890 212 7.34
(6.39-8.29)
2890 91 3.15
(2.51-3.79)
2620 170 6.49
(5.55-7.43)
Abbreviations: ARIC, Atherosclerosis Risk in Communities; CI, confidence interval; InCHIANTI, Invecchiare in Chianti; IQR, interquartile range; NA, data not available; PAOD, peripheral
arterial occlusive disease.
aDefined as death due to coronary heart disease or stroke.
bDefined as myocardial infarction or deaths from coronary heart disease.
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lower than in the higher FRS catego-
ries. Women had especially high mor-
tality and event rates in the lowest FRS
category. Men andwomenwith an ABI
from 0.91 to 1.10 also had higher mor-
tality and event rates compared with
thosewith a normalABI (1.11-1.40) but
the magnitudes of the increase were
much less than for those with an ABI
of 0.90 or less. Those with an ABI
greater than 1.40 also had higher rates
across most FRS categories.
Inclusion of the ABI had an overall
effect on the prediction of events, es-
pecially in women. When predicting
major coronary events using only the
FRS, the area under the receiver oper-
ating characteristic curve was 0.646
(95%CI, 0.643-0.657) andwith the ad-
dition of the ABI was 0.655 (95% CI,
0.643-0.666) inmen vs 0.605 (95%CI,
Table 4. Hazard Ratios (HRs) for Total Mortality, Cardiovascular Mortality, and Major Coronary Events by Ankle Brachial Index (ABI) at
Baseline for Men in All Studies Combined in the ABI Collaboration
ABI
0.60 0.61-0.70 0.71-0.80 0.81-0.90 0.91-1.00 1.01-1.10 1.11-1.20 1.21-1.30 1.31-1.40 1.40
Sample size
(n = 24955)
360 279 428 774 2438 5775 7576 4936 1681 708
Total Mortality
No. of deaths
(n = 5582)
215 170 217 355 741 1338 1364 745 270 167
HR
(95% CI)a
4.06
(3.51-4.70)
3.88
(3.30-4.55)
3.15
(2.73-3.64)
2.47
(2.19-2.78)
1.61
(1.47-1.77)
1.22
(1.13-1.32)
1
[Reference]
0.86
(0.78-0.94)
0.94
(0.83-1.07)
1.38
(1.17-1.62)
Cardiovascular Mortalityb
No. of deaths
(n = 1507)
80 54 81 116 208 352 341 179 62 34
HR
(95% CI)a
5.58
(4.36-7.15)
4.60
(3.44-6.14)
4.49
(3.51-5.74)
3.03
(2.45-3.75)
1.68
(1.40-2.00)
1.24
(1.07-1.44)
1
[Reference]
0.85
(0.71-1.02)
0.93
(0.71-1.22)
1.14
(0.80-1.63)
Major Coronary Events (n = 21433)c
No. of events
(n = 2255)
70 48 74 119 252 516 642 353 125 56
HR
(95% CI)a
3.45
(2.68-4.43)
2.71
(2.01-3.64)
2.76
(2.16-3.52)
2.15
(1.76-2.63)
1.43
(1.23-1.66)
1.12
(1.00-1.26)
1
[Reference]
0.78
(0.68-0.88)
0.78
(0.64-0.95)
0.90
(0.68-1.18)
Abbreviation: CI, confidence interval.
aThe HRs are not adjusted for age or cardiovascular risk factors.
bDefined as death due to coronary heart disease or stroke.
cDefined as myocardial infarction or deaths from coronary heart disease.
Table 5. Hazard Ratios (HRs) for Total Mortality, Cardiovascular Mortality, and Major Coronary Events by Ankle Brachial Index (ABI) at
Baseline for Women in All Studies Combined in the ABI Collaboration
ABI
0.60 0.61-0.70 0.71-0.80 0.81-0.90 0.91-1.00 1.01-1.10 1.11-1.20 1.21-1.30 1.31-1.40 1.40
Sample size
(n = 23339)
314 251 403 933 3186 6586 6862 3363 932 509
Total Mortality
No. of deaths
(n = 4342)
199 145 174 326 707 1078 999 489 125 100
HR
(95% CI)a
4.89
(4.19-5.71)
3.88
(3.25-4.63)
2.61
(2.22-3.08)
2.08
(1.83-2.36)
1.52
(1.38-1.67)
1.11
(1.02-1.21)
1
[Reference]
1.00
(0.90-1.12)
0.91
(0.75-1.10)
1.23
(1.00-1.52)
Cardiovascular Mortalityb
No. of deaths
(n = 1211)
79 51 66 114 218 271 241 119 24 28
HR
(95% CI)a
7.04
(5.43-9.12)
5.06
(3.72-6.87)
3.65
(2.77-4.81)
2.77
(2.21-3.47)
1.84
(1.53-2.22)
1.14
(0.95-1.36)
1
[Reference]
1.04
(0.83-1.29)
0.74
(0.49-1.13)
1.48
(1.00-2.21)
Major Coronary Events (n = 22486)c
No. of events
(n = 1629)
79 54 64 119 260 412 387 174 47 33
HR
(95% CI)a
5.43
(4.24-6.94)
3.82
(2.86-5.11)
2.58
(1.97-3.37)
2.06
(1.67-2.53)
1.53
(1.30-1.79)
1.11
(0.97-1.28)
1
[Reference]
0.91
(0.76-1.09)
0.86
(0.64-1.17)
1.11
(0.77-1.58)
Abbreviation: CI, confidence interval.
aThe HRs are not adjusted for age or cardiovascular risk factors.
bDefined as death due to coronary heart disease or stroke.
cDefined as myocardial infarction or deaths from coronary heart disease.
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0.590-0.619) and0.658 (95%CI, 0.644-
0.672), respectively, in women.
TheFRS ismostly used to predict risk
of totalCHD(including coronary death,
myocardial infarction, and angina) and
TABLE 8 shows the effect of including
the ABI on this prediction. The cali-
bration of the FRS categories was rea-
sonable because the overall CHD rate
in each FRS category was within the
range predicted, except for low-risk
women in which the overall CHD rate
of 11%was higher than predicted. Like-
wise, the ability of the FRS to discrimi-
nate between risk categories was good,
except that the overall CHD rate in
women in the low-risk group was only
slightly lower than those in the inter-
mediate-risk group (11% vs 13%). In
each category of FRS in both men and
women, a low ABI (0.90) was asso-
ciated with an increased risk of future
CHD. Normal levels of the ABI (1.11-
1.40)were associatedwith a slightly re-
duced risk from the overall rates but lev-
els greater than 1.40 did not differ
consistently from the overall rates, al-
Figure 3. Random Hazard Ratios for Total Mortality for Low (0.90) Compared With Normal (1.11-1.40) Ankle Brachial Index (ABI) in Men
in Studies in the ABI Collaboration
No. of Men
Hazard Ratio (95% CI)
0.1 100101
ABI ≤ 0.90 ABI, 1.11-1.40
No. of Deaths
ABI ≤ 0.90 ABI, 1.11-1.40Study
Hazard Ratio
(95% CI)
25 1544 4 64Belgian Physical Fitness,17 1995
129 4446 64 568ARIC,9 2007
220 1005 177 330Cardiovascular Health,10 1999
94 316 69 111Edinburgh Artery,13 1996
38 1120 9 72Framingham Offspring,19 2002
391 1048 204 226Honolulu Heart Program,11 2000
Hoorn,21 1999 30 83 20 16
InCHIANTI,22 2004 53 151 7 8
Limburg PAOD,14 2004 89 459 31 36
Men Born in 1914,15 1993 46 79 35 32
Rotterdam,16 2004 318 1133 200 317
San Diego,23 1992 30 103 28 62
San Luis Valley Diabetes,24 1995 15 479 10 106
Strong Heart,12 2004 75 1006 23 288
Overall 1841 14 193 957 2379
Test for overall effect: z = 11.98; P<.001
288 1221 76 143Health in Men,20 2002
4.15 (1.52-11.37)
5.23 (4.04-6.77)
4.48 (3.72-5.39)
2.84 (2.10-3.84)
4.67 (2.33-9.34)
3.00 (2.48-3.63)
5.34 (2.74-10.39)
2.11 (0.75-5.93)
5.50 (3.40-8.90)
3.06 (1.89-4.96)
3.25 (2.72-3.88)
2.97 (1.88-4.69)
4.25 (2.22-8.13)
1.06 (0.69-1.62)
3.33 (2.74-4.06)
2.50 (1.89-3.30)
Test for heterogeneity: χ14 = 64.32; P<.001; I2 = 78.2% 2
Hazard ratios are not adjusted for age or cardiovascular risk factors. Area of each square is proportional to weight of the study in the meta-analysis. ARIC indicates
Atherosclerosis Risk in Communities; CI, confidence interval; InCHIANTI, Invecchiare in Chianti; PAOD, peripheral arterial occlusive disease.
Figure 4. Random Hazard Ratios for Total Mortality for Low (0.90) Compared With Normal (1.11-1.40) Ankle Brachial Index (ABI) in
Women in Studies in the ABI Collaboration
No. of Women
Hazard Ratio (95% CI)
0.1 100101
ABI ≤ 0.90 ABI, 1.11-1.40
No. of Deaths
ABI ≤ 0.90 ABI, 1.11-1.40Study
Hazard Ratio
(95% CI)
268 4441 66 393ARIC,9 2007
297 1134 159 280Cardiovascular Health,10 1999
133 192 50 46Edinburgh Artery,13 1996
46 887 3 27Framingham Offspring,19 2002
Hoorn,21 1999 23 62 15 11
InCHIANTI,22 2004 37 176 8 4
Limburg PAOD,14 2004 84 486 18 33
Rotterdam,16 2004 657 1498 383 324
San Diego,23 1992 47 81 29 45
Strong Heart,12 2004 143 1540 24 325
San Luis Valley Diabetes,24 1995 19 364 11 63
Women’s Health and Aging,25 2000 147 296 78 62
Overall 1901 11 157 844 1613
3.17 (2.44-4.11)
3.05 (2.51-3.71)
1.77 (1.19-2.64)
2.38 (0.72-7.86)
5.42 (2.48-11.84)
10.50 (3.16-34.88)
3.34 (1.88-5.94)
3.75 (3.23-4.36)
1.25 (0.78-2.00)
0.77 (0.51-1.16)
4.37 (2.30-8.30)
3.22 (2.30-4.50)
2.71 (2.03-3.62)
Test for overall effect: z = 6.73; P<.001
Test for heterogeneity: χ11 = 78.97; P<.001; I2 = 86.1%2
Hazard ratios are not adjusted for age or cardiovascular risk factors. Area of each square is proportional to weight of the study in the meta-analysis. ARIC indicates
Atherosclerosis Risk in Communities; CI, confidence interval; InCHIANTI, Invecchiare in Chianti; PAOD, peripheral arterial occlusive disease.
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though this may have been influenced
by the relatively low numbers of par-
ticipants.
The results in Table 8 also indicate
in which categories of FRS the ABI is
likely to change individuals’ clinical risk
levels (ie, between 10%, 10%-19%,
and20%). Inmen, the greatest effect
would be in high-risk individuals
(20%) with a normal ABI (1.11-
1.40) in whom the risk level would be
reduced to intermediate (10%-19%).All
menwith a lowABI (0.90) had a rela-
tively high risk but their clinical risk
level would not change from that pre-
dicted overall by the FRS. In women,
the main effect of the ABI would be to
change all women in the low FRS cat-
egory (10%) with an abnormal ABI
(0.90 or 0.91 to 1.10 or1.40) to a
higher risk level. Alsowomen in the in-
termediate FRS category (10%-19%)
with a low ABI (0.90) would be-
come high risk (20%). Table 8 also
shows that the number of men chang-
ing risk category (shaded numbers)
would be 4106 of 21 433 (19%) and in
women would be 8154 of 22 486
women (36%).
COMMENT
Predicting futureCHDandmortality ac-
curately in individuals in the commu-
nity who have no prior history of car-
diovascular disease has proven difficult
when based solely on traditional risk
factors and scoring systems. In a re-
cent systematic review of 27 studies
using the Framingham risk equation,
the predicted-to-observed ratios ranged
from an underprediction of 0.43 in
a high-risk population to an overpre-
diction of 2.87 in a low-risk popula-
tion.4 We found that the ABI provided
independent risk information com-
pared with the FRS and, when com-
bined with the FRS, a low ABI (0.90)
approximately doubled the risk of
total mortality, cardiovascular mortal-
ity, and major coronary events across
all Framingham risk categories.
In predicting the 10-year risk of total
CHD, our results (Table 8) indicate that
approximately 1 of 5 men would have
their broad category of risk (10, 10-
19, 20%) changed from that pre-
dicted by FRS alone to that found on
inclusion of the ABI. These changes
from higher to lower categories of risk
would likely have an effect on deci-
sions to commence preventive treat-
ment, such as lipid-lowering therapy,
as recommended in the Adult Treat-
ment Panel III guidelines.27 In con-
trast, the main effect in women of in-
clusion of the ABI would be that many
at low riskwith the FRS (10%)would
change to a higher risk level. In total,
around 1 in 3 women would be af-
fected. It should be recognized, how-
ever, that the proportion of men and
women affected by inclusion of the ABI
Table 6. 10-Year Total Mortality, Cardiovascular Mortality, and Major Coronary Event Rates in Men by Framingham Risk Category and Ankle
Brachial Index (ABI) at Baseline for All Studies Combined in the ABI Collaborationa
Framingham Risk
Categoryb
ABI
Overall0.90 0.91-1.10 1.11-1.40 1.40
Total Mortality, % (95% CI)
1 (Lowest; n = 5746) 27.1 (16.0-38.2) 11.4 (5.9-16.8) 8.3 (5.4-11.2) 14.1 (4.2-24.0) 10.4 (6.9-13.9)
2 (n = 4319) 37.3 (17.8-56.9) 15.8 (10.6-21.0) 11.3 (8.2-14.5) 19.9 (7.5-32.4) 13.8 (9.9-17.7)
3 (n = 3544) 37.6 (26.1-49.1) 19.7 (13.6-25.9) 14.2 (9.9-18.5) 23.5 (9.5-37.6) 17.6 (13.1-22.2)
4 (n = 5814) 38.1 (28.5-47.8) 23.6 (16.9-30.4) 19.2 (14.8-23.5) 38.4 (12.3-64.6) 23.1 (17.6-28.6)
5 (Highest; n = 5532) 57.1 (45.4-68.9) 36.4 (29.1-43.7) 31.0 (25.2-36.7) 43.6 (28.1-59.1) 38.0 (30.9-45.0)
Overall (n = 24 955) 46.3 (36.1-56.6) 23.0 (15.8-30.2) 16.7 (12.4-21.0) 29.2 (18.9-39.5)
Cardiovascular Mortality, % (95% CI)
1 (Lowest; n = 5746) 4.6 (0.0-10.8) 3.1 (0.0-6.5) 1.3 (0.5-2.0) 2.7 (0.0-6.8) 1.6 (0.8-2.4)
2 (n = 4319) 17.5 (6.6-28.3) 3.5 (1.5-5.5) 1.5 (0.7-2.3) 8.2 (0.0-18.8) 2.3 (1.3-3.4)
3 (n = 3544) 11.5 (2.4-20.6) 5.1 (3.1-7.2) 3.6 (1.9-5.2) 8.3 (0.3-16.2) 4.4 (2.8-6.0)
4 (n = 5814) 14.2 (10.2-18.2) 8.0 (5.2-10.8) 4.8 (3.3-6.4) 5.6 (0.0-12.2) 7.3 (5.2-9.3)
5 (Highest; n = 5532) 27.9 (20.7-35.1) 12.5 (8.9-16.1) 9.9 (6.8-13.1) 10.7 (2.0-19.4) 14.0 (10.6-17.4)
Overall (n = 24 955) 18.7 (13.3-24.1) 7.3 (5.0-9.6) 4.4 (3.2-5.7) 6.9 (2.8-11.0)
Major Coronary Events, % (95% CI)c
1 (Lowest; n = 5643) 5.8 (0.0-12.7) 3.7 (1.4-6.0) 3.4 (2.5-4.3) 4.0 (1.1-6.8) 3.5 (2.4-4.6)
2 (n = 4151) 20.0 (9.6-30.4) 5.9 (3.6-8.1) 6.8 (5.7-8.0) 5.0 (0.7-9.3) 7.1 (5.5-8.8)
3 (n = 3241) 20.2 (8.0-32.3) 10.0 (6.2-13.8) 8.7 (6.4-11.0) 12.9 (0.0-27.8) 10.1 (7.5-12.6)
4 (n = 4179) 27.5 (18.5-36.6) 14.8 (9.9-19.7) 12.6 (9.6-15.7) 9.7 (0.0-19.7) 15.3 (11.5-19.1)
5 (Highest; n = 4219) 31.4 (21.9-40.8) 20.0 (14.4-25.5) 17.6 (12.2-23.0) 12.0 (3.6-20.3) 21.5 (16.7-26.3)
Overall (n = 21 433) 26.8 (19.5-34.1) 12.9 (9.2-16.7) 9.4 (7.4-11.4) 7.2 (4.3-10.1)
Abbreviation: CI, confidence interval.
aAnalysis based on random-effects pooling of Kaplan-Meier estimates from the individual studies.
bCategories of predicted 10-year percentage incidence of coronary heart disease, including coronary death, myocardial infarction, and angina are based on whole number cut
points for scores (category 1, 10%; 2, 10%-14%; 3, 15%-19%; 4, 20%-29%; 5, 30%).
cExcludes Health in Men,20 Hoorn,21 and InCHIANTI22 studies.
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is approximate due to themethod of es-
timating total CHD end points and pos-
sible residual confounding within the
FRS categories.
Our results also confirm the recent
findings of the Strong Heart Study,12
Cardiovascular Health Study,28 and
Multi-ethnic Study of Atherosclero-
sis29 that the relationship between ABI
and cardiovascular disease is nonlin-
ear and varies across the range of ABI.
High values (1.40) could be related
to poor arterial compressibility result-
ing from stiffness and calcification,
which may occur more commonly in
those with diabetes,29,30 and may be 1
explanation why those with an ABI
greater than 1.40 are at increased risk.
The differences in risk betweenABI val-
ues from 1.11 to 1.40 in both men and
women were so small that, for practi-
Table 7. 10-Year Total Mortality, Cardiovascular Mortality, and Major Coronary Event Rates in Women by Framingham Risk Category and
Ankle Brachial Index (ABI) at Baseline for All Studies Combined in the ABI Collaborationa
Framingham Risk
Categoryb
ABI
Overall0.90 0.91-1.10 1.11-1.40 1.40
Total Mortality, % (95% CI)
1 (Lowest; n = 5507) 44.2 (7.5-80.9) 21.3 (12.5-30.1) 14.1 (9.1-19.1) 27.4 (14.6-40.2) 18.2 (10.6-25.8)
2 (n = 6016) 28.2 (9.2-47.2) 13.3 (7.7-18.9) 10.3 (6.3-14.3) 8.1 (1.9-14.3) 12.2 (7.0-17.4)
3 (n = 5581) 27.1 (16.0-38.1) 15.2 (11.0-19.4) 10.9 (7.5-14.2) 20.6 (11.7-29.5) 15.7 (11.2-20.2)
4 (Highest; n = 6235) 31.4 (23.2-39.7) 17.6 (13.3-21.9) 16.2 (12.2-20.3) 20.9 (0.0-48.2) 19.8 (16.6-23.0)
Overall (n = 23 339) 30.1 (18.0-42.1) 16.6 (10.9-22.3) 13.1 (8.5-17.6) 26.6 (9.7-43.4)
Cardiovascular Mortality, % (95% CI)
1 (Lowest; n = 5507) 45.5 (29.7-61.4) 4.5 (1.9-7.0) 4.0 (1.6-6.4) 14.1 (0.0-32.3) 4.8 (3.2-6.4)
2 (n = 6016) 15.1 (1.5-28.7) 4.1 (1.6-6.6) 2.9 (0.9-4.9) 4.3 (0.0-12.7) 3.5 (1.6-5.4)
3 (n = 5581) 9.7 (5.1-14.3) 4.4 (2.5-6.3) 3.2 (1.5-4.8) 14.7 (0.0-45.6) 4.8 (3.0-6.6)
4 (Highest; n = 6235) 15.7 (9.5-22.0) 5.1 (3.4-6.9) 5.5 (3.5-7.6) 15.5 (8.4-22.5) 6.8 (4.5-9.2)
Overall (n = 23 339) 12.6 (6.2-19.0) 4.7 (3.0-6.3) 4.1 (2.2-6.1) 6.9 (4.0-9.7)
Major Coronary Events, % (95% CI)c
1 (Lowest; n = 5355) 29.9 (9.0-50.8) 3.9 (1.7-6.1) 5.3 (2.4-8.2) 10.7 (0.0-24.3) 5.8 (3.9-7.7)
2 (n = 5842) 16.9 (6.8-27.1) 5.1 (2.4-7.7) 3.7 (2.0-5.5) 2.1 (0.0-6.3) 4.7 (2.6-6.7)
3 (n = 5334) 15.3 (8.0-22.6) 7.5 (4.5-10.4) 5.2 (3.5-6.9) 14.1 (0.0-47.9) 6.7 (4.3-9.1)
4 (Highest; n = 5955) 23.3 (14.5-32.0) 9.8 (7.4-12.2) 9.4 (6.7-12.0) 14.9 (8.8-21.1) 11.9 (9.3-14.5)
Overall (n = 22 486) 18.9 (11.6-26.2) 7.3 (5.0-9.6) 6.1 (4.1-8.1) 5.5 (0.7-10.3)
Abbreviation: CI, confidence interval.
aAnalysis based on random-effects pooling of Kaplan-Meier estimates from the individual studies.
bCategories of predicted 10-year percentage incidence of coronary heart disease, including coronary death, myocardial infarction, and angina are based on whole number cut
points for scores (category 1, 4%; 2, 5%-7%; 3, 8%-11%; 4, 12%).
cExcludes Hoorn21 and InCHIANTI22 studies.
Table 8. 10-Year Total Coronary Heart Disease (CHD) Rates in Men and Women by Framingham Risk Score (FRS) Category and Ankle
Brachial Index (ABI) at Baseline for All Studies Combined in the ABI Collaborationa
FRS Categoryb
Total
ABI
0.90 0.91-1.10 1.11-1.40 1.40
No. in
FRS
Category
CHD,
%c
No. in
FRS
Category
CHD,
%c
No. in
FRS
Category
CHD,
%c
No. in
FRS
Category
CHD,
%c
No. in
FRS
Category
CHD,
%c
Men
Low (10%) 5643 5 76 8 1076 5 4255 4 236 5
Intermediate (10%-19%) 7392 13 245 16 2069 12 4815 12 263 8
High (20%) 8398 23 1149 40 3406 21 3668 18 175 14
Women
Low (10%) 15 505 11 1083 21 6192 10 7909 9 321 11
Intermediate (10%-19%) 5563 13 558 25 2429 12 2433 11 143 13
High (20%) 1418 27 200 44 598 21 577 22 43 34
aExcludes Health in Men,20 Hoorn,21 and InCHIANTI22 studies, in which nonfatal events were not available. Shaded numbers indicate individuals who would change between low
(10%), intermediate (10%-19%), and high (20%) risk categories from that predicted by the FRS when ABI was included. Analysis based on random-effects pooling of Kaplan-
Meier estimates from the individual studies.
bCategories of predicted 10-year percentage incidence of coronary heart disease, including coronary death, myocardial infarction, and angina.
c Includes coronary death, myocardial infarction, and angina. Rates are approximate based on observed major coronary events (coronary death or myocardial infarction) adjusted
by established conversion factors.26 The number of individuals indicates those with the specified Framingham risk category and ABI level, irrespective of whether they have coro-
nary heart disease.
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cal purposes, an ABI within this range
could be considered normal. Individu-
als with an ABI from 0.91 to 1.10 were
at slightly increased risk. These re-
sults would suggest that the widely ac-
cepted high-risk cut point of 0.90 is rea-
sonable. However, for ABI values from
0.91 to 1.10 and greater than 1.40, in-
dividuals might be advised that their
risk may be slightly higher than nor-
mal levels.
The ABI Collaboration includes 16
international cohort studies. The con-
sistency of results, especially in men
(Figure 3), across a diverse spectrum
of populations strengthens the valid-
ity of our findings. This consistency also
was apparent despite some differences
in methods of measuring the ABI and
in ascertaining outcome events.We did
not recalibrate the FRS, as has been sug-
gested in populations very different
from that in Framingham,31 because in
our collaboration there was no evi-
dence that particular studies had sub-
stantially worse calibration than oth-
ers and also the FRS when used in
routine clinical practice is not usually
calibrated to the local population. Al-
though the area under receiver oper-
ating characteristic curves examining
the added effect of the ABI are pre-
sented, from a clinical perspective, the
added value of the ABI is the extent to
which its inclusion reclassifies patient
risk at an individual level.32
Other indicators of asymptomatic
atherosclerosis, notably coronary artery
calcium score and carotid intimamedia
thickness have been evaluated as incre-
mental riskpredictors to theFRS.Popu-
lationstudiesof apparentlyhealthy indi-
viduals have suggested that coronary
artery calciumscoremayprovide added
value,33,34 particularly in discriminat-
ing high- and low-risk individualswith
an intermediate FRS (predicted 10-year
coronary event risk between 10% and
20%).35 In the Atherosclerosis Risk in
Communities study,36 inclusion of
carotid intima media thickness had a
modest effect on the area under the
receiver operating characteristic curve
for the prediction of CHD using tradi-
tional risk factors. Likewise, in patients
with dyslipidaemia37 and diabetes,38 a
combination of carotid intima media
thickness and FRS improved predic-
tion compared with FRS alone.We are
not aware, however, of reports of any
direct comparisons in the same study
of the additional values in which dif-
ferent measures of asymptomatic ath-
erosclerosis (eg, coronary artery cal-
ciumvs carotid intimamedia thickness)
make to FRS prediction in the general
population.
The ABI is potentially a useful tool
for prediction of cardiovascular risk. In
contrast tomeasurement of coronary ar-
tery calcium and carotid intima media
thickness, it has the advantage of ease
of use in the primary care physician’s
office and in community settings. The
equipment is inexpensive—a hand-
held Doppler costs less than $600. The
procedure is simple, taking less than 10
to 15 minutes,39,40 and can be per-
formed by a suitably trained nurse or
other health care professional. Tech-
nological advances to make the test
quicker and easier to apply are being
investigated, including automatic pres-
suremeasurement at the ankle.41 Given
the noninvasiveness of the test and
minimal discomfort, patient acceptabil-
ity is high. Variability is comparable
with that of routine blood pressure42,43
and individuals with borderline re-
sults may benefit from a repeatedmea-
sure at a different visit.43
Although widely used in specialist
vascular clinics, the ABI is rarely ap-
plied in routine clinical practice. Bar-
riers to its use include: (1) most clini-
cians are not aware that a low ABI is a
marker of cardiovascular risk; (2) it is
perceived as a specialist test for use only
by vascular surgeons and physicians;
and (3)most clinicianswould not know
how to perform the test. Physician edu-
cation would be essential in promot-
ing use of the ABI in practice. Further-
more, in a survey of physicians primed
to use the ABI in 1 program in the
United States, time constraints, lack of
reimbursement, and staff availability
were barriers to use of the ABI, each re-
ported by around half the physi-
cians.40
The yield of a screening test also is
important. Our results indicate that a
proportion of men and women having
an ABI test would be placed in a dif-
ferent risk category. However, this pro-
portion may vary considerably by age
because the prevalence of a low ABI is
known to increase substantially with
age. For example, in the United States
in 2000, the prevalence of an ABI lower
than 0.90 in non–Hispanic white men
aged 40 to 49 years was 1.4% but was
22.6% in those aged 80 years or older.44
Significantly higher prevalences were
found in blacks. In 12 300 men free of
cardiovascular disease in the general
population in Scotland, the preva-
lence of an ABI of 0.90 or less in those
aged 50 to 54 years was 3.7% but was
12.7% in those aged 75 years or older.45
While recognizing that most risk fac-
tors also increase with age, it is likely
that the added yield of a lowABI is age-
related.
Recently published guidelines by the
American Heart Association and the
American College of Cardiology,46 the
Transatlantic Inter-Society Consen-
sus Working Group,47 and the Fourth
Joint European Task Force48 have sug-
gested that the ABI should be consid-
ered for the purposes of cardiovascu-
lar risk assessment. The results of our
study indicate that,whenusing theFRS,
this may indeed be justified to im-
prove prediction of cardiovascular risk
and provision of advice on ways to re-
duce that risk. A new risk equation in-
corporating the ABI and relevant
Framingham risk variables couldmore
accurately predict risk and our inten-
tion is to develop and validate such a
model in our combined data set. Cost-
effectiveness modeling of the effect of
using theABI on long-term clinical out-
comes also would be of interest, as has
been recommended recently by an
American Heart Association expert
working group on screening for ath-
erosclerotic peripheral vascular dis-
ease (Michael H. Criqui, MD, Univer-
sity of California San Diego, written
communication, January 2008). A cost-
effectiveness analysis also would be
useful because successful implemen-
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tation of the ABI in programs for as-
sessment of cardiovascular risk would
require a change in reimbursement
regulations in some countries.
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